Condition
Stage IIIA Lung Cancer
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Withdrawn1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07153445Phase 2Recruiting
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT06427369Phase 1Withdrawn
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
Showing all 2 trials